Premium
Carprofen inhibition of flare in the dog measured by laser flare photometry
Author(s) -
Krohne S.G.,
Blair M.J.,
Bingaman D.,
Gionfriddo J.R.
Publication year - 1998
Publication title -
veterinary ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.594
H-Index - 50
eISSN - 1463-5224
pISSN - 1463-5216
DOI - 10.1046/j.1463-5224.1998.00016.x
Subject(s) - carprofen , flare , anesthesia , pilocarpine , medicine , chemistry , pharmacology , physics , psychiatry , astrophysics , epilepsy
The purpose of this study was to determine whether oral carprofen (Rimadyl®) treatment in dogs could prevent or decrease the breakdown of the blood–aqueous barrier. The topical pilocarpine irritative model was used to induce breakdown and cause flare. Pilocarpine was instilled in both eyes of seven dogs at time zero and again 5 h later. At 7 h, laser flare photometry was used to measure the flare concentration in each eye using the Kowa FC‐1000 laser flare cell meter. All treatments were then discontinued. Two days later, carprofen was administered to the same dogs for a total of three doses. After the last dose of carprofen, pilocarpine treatments and flare measurements were repeated. Carprofen pretreatment resulted in a 68% inhibition of flare, which was highly significant ( P < 0.01). The pilocarpine group had a mean of 16.1 photon counts per millisecond (PC ms −1 ) ± 2.2 SE, and the carprofen group had a mean of 7.0 PC/ms ± 1.2 SE. These results compare favorably with previous studies measuring increased protein or fluorescein concentrations in the aqueous humor after blood–aqueous barrier breakdown in the dog. These results suggest that carprofen may be effectively used as a systemically administered ocular anti‐inflammatory drug. Carprofen has the added benefit of fewer reported side effects.